Lacquaniti eyes expansion

Share this article:

The selection process was described as extensive and exhaustive, but now that Mary Lacquaniti is settling into her new role as executive director of the Healthcare Marketing and Communications Council (HMC), she is focused on the future.
"This is very exciting," she said in an interview this week, noting that one of her priorities is to continue "to add value" for HMC's roughly 1,100 members. "We have some key volunteers [and] we have a series of new initiatives," she added. "We just want to expand those and make sure we are meeting the needs of our members."
Among the initiatives is HMC University, a new "framework" for the education platform and which aims to be a continuing resource for healthcare marketers throughout their career. "We want to see all of our educational initiatives on more of an educational platform," Lacquaniti said. "We want to make sure our existing programs remain current and we have a great group of volunteers taking great initiative."
The HMC University program is in development, and Lacquaniti said she anticipates more announcing more details HMC University programs in the next month.
Laquaniti served as HMC's associate director since 2001 and had joined the staff as a program manager in March 1999. In June she earned the Certified Association Executive credential form the American Society of Association Executives. Lacquaniti succeeded Richard Sawyer, who had held the top post at HMC since 1992.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...